Key result
In patients with hyperlipoproteinemia (a), comprehensive risk management and targeted LDL-cholesterol lowering are mandatory for cardiovascular prevention since specific medical treatments for Lp(a) are lacking.
Answers are grounded in this paper and cite their sources.
This review emphasizes the importance of early risk stratification and aggressive management of conventional risk factors, including LDL-C lowering and apheresis, in patients with elevated Lp(a).
General lipoprotein (Lp) (a) screening can help to identify patients at high risk for cardiovascular disease. Non-invasive methods allow early detection of clinically asymptomatic incipient atherosclerotic disease. Medical treatment options are still unsatisfactory. Lp(a) apheresis is an established treatment in Germany for secondary prevention of progressive cardiovascular disease. Statin-based lowering of LDL cholesterol and thrombocyte aggregation inhibitors still represent the basis of medical treatment. Target levels for LDL-cholesterol should be modified in patients with hyperlipoproteinemia (a).
No takes yet. Share an insight, caveat, or question.
Grützmacher et al. (2017) conducted a review in Hyperlipoproteinemia (a). Lipoprotein (a) apheresis and lipid-lowering therapies was evaluated. In patients with hyperlipoproteinemia (a), comprehensive risk management and targeted LDL-cholesterol lowering are mandatory for cardiovascular prevention since specific medical treatments for Lp(a) are lacking.
Synapse has enriched 10 related papers. Consider them for comparative context: